Tesamorelin + Ipamorelin Blend (15 mg)

Overview

The Tesamorelin + Ipamorelin co-lyophilised vial applies the same dual-pathway GH-axis logic as the canonical CJC-1295 + Ipamorelin SKU, but substitutes Tesamorelin in the GHRH-receptor seat. Two practical consequences flow from the substitution. First, Tesamorelin is the only FDA-approved member of the GHRH-analogue class as a finished drug (Egrifta, for HIV-associated lipodystrophy), giving the bulk active a regulatory and clinical pedigree that CJC-1295 lacks. Second, Tesamorelin's half-life and pharmacokinetic envelope differ slightly from CJC-1295 no-DAC, which translates to somewhat different GH-release kinetics inside dual-pathway compounding protocols. The underlying mechanism, GHRH-receptor activation plus GHSR-receptor activation converging on the same somatotroph cells, is preserved. Vialdyne releases this blend as a co-lyophilised 15 mg total-mass vial against a ≥99.0% main-peak HPLC specification per component. The default split is 10 mg of the Tesamorelin component paired with 5 mg of the Ipamorelin component, reflecting the typical mass-equivalent imbalance that 503A compounding protocols use when Tesamorelin is the GHRH-receptor agonist in play. Non-standard ratios are scoped under a project-specific change-control. The released-batch COA certifies both component purities individually and the actual in-vial ratio rather than just the nominal target.

Who buys this, and why

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.

Specifications

CAS

(blend, components have individual CAS numbers)

Purity (HPLC)

≥ 99.0% (component-wise for blends)

Common vial sizes

15 mg

MOQ

On request

Lead time

14–21 days

Storage

-20°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• Ratio-verification HPLC
• Mass-spec identity of each component
• Stability of the blend (matrix-specific)
• Bacterial endotoxin (LAL, USP <85>)
• Sterile-fill documentation (where applicable)
• SDS / MSDS
• Private-label / OEM specification sheet

Regulatory note

Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.

Frequently asked questions